A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback